Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2013 | comment

ASCO 2013—new concepts and the path to individualized therapy

verfasst von: Univ. Prof. Dr. Heinz Zwierzina

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

At American Society of Clinical Oncology’s 2013 meeting, the clinical development of innovative drugs targeting the immune system and progress in biomarker research represented some of the highlights. During recent years, immunomodulatory agents have become a very active field in clinical cancer research. After the successful development of the anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) antibody ipilimumab in melanoma, the “programmed cell death protein 1” pathway is expected to become a cornerstone in several tumor types. One key challenge for anticancer treatment, in general, is the definition of biomarkers and the further individualization of therapy. Progress in molecular phenotyping and in serum proteomics as predictive markers was reported.
Vorheriger Artikel Update on neurooncology Annual meeting of the American Society of Clinical Oncology (ASCO) 2013
Nächster Artikel Transfusion-associated graft-versus-host disease: an update
Literatur
1.
Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A, Segal N, Ariyan C, Gordon R, Reed K, Burke M, Caldwell A, Kronenberg S, Agunwamba B, Zhang X, Lowy I, Inzunza H, Feely W, Horak C, Hong Q, Korman A, Wigginton J, Gupta A, Sznol M. Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.
2.
Gatalica Z, Millis S, Chen S, Dan Basu G, Wen W, Paul L, Bender R, Von Hoff D. Integrating molecular profiling into cancer treatment decision making: Experience with over 35,000 cases. J Clin Oncol. 31, 2013 (suppl; abstr 11001).
3.
Lazzari C, Novello S, Barni S, Aieta M, De Marinis F, De Pas T, Grossi F, Mencoboni M, Bearz A, Floriani I, Torri V, Bulotta A, Grigorieva J, Roder J, Doglioni C, Roder H, Righi L, Foti S, Bachi A, Gregorc V. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). J Clin Oncol 31, 2013 (suppl; abstr LBA8005).
Metadaten
Titel
ASCO 2013—new concepts and the path to individualized therapy
verfasst von
Univ. Prof. Dr. Heinz Zwierzina
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0123-7

Weitere Artikel der Ausgabe 4/2013

ASCO 2013—treatment of metastatic melanoma: is it still a story of success?

  • short review

T-DM1 in breast cancer therapeutics: the first drug of its generation

  • review

ASCO 2013: news in early-stage and advanced breast cancer

  • short review

Antibody–drug conjugates (ADCs)—new targeted therapies

  • editorial

ASCO 2013: new developments in lung cancer

  • short review

Update on neurooncology Annual meeting of the American Society of Clinical Oncology (ASCO) 2013

  • short review